Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Journal of Clinical Oncology · 10.09.2023 · 41 (26) · 4208-4217
DOI: 10.1200/jco.23.00515 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2023. Verfasst von Byoung Chul Cho und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 159-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were 18 years and older with no previous systemic anticancer therapy. Neurologically stable patients with CNS metastases were allowed. Patients were randomly assigned 1:1 to lazertinib 240 mg once daily orally or gefitinib 250 mg once daily orally, stratified by mutation status and race. The primary end point was investigator-assessed progression-free survival (PFS) by RECIST v1.1. RESULTS Overall, 393 patients received double-blind study treatment across 96 sites in 13 countries. Median PFS was significantly longer with lazertinib than with gefitinib (20.6 v 9.7 months; hazard ratio [HR], 0.45; 95% CI, 0.34 to 0.58; P < .001). The PFS benefit of lazertinib over gefitinib was consistent across all predefined subgroups. The objective response rate was 76% in both groups (odds ratio, 0.99; 95% CI, 0.62 to 1.59). Median duration of response was 19.4 months (95% CI, 16.6 to 24.9) with lazertinib versus 8.3 months (95% CI, 6.9 to 10.9) with gefitinib. Overall survival data were immature at the interim analysis (29% maturity). The 18-month survival rate was 80% with lazertinib and 72% with gefitinib (HR, 0.74; 95% CI, 0.51 to 1.08; P = .116). Observed safety of both treatments was consistent with their previously reported safety profiles. CONCLUSION Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- National University Hospital, Singapore, Singapore.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A Soo, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Ahmet Sezer, Pongwut Danchaivijitr, YuKyung Kim, Hae Mi Byun, Bojan Zaric
Zitieren
APA
Cho, B. C., Ahn, M. J., Kang, J. H., Soo, R. A., Reungwetwattana, T., Yang, J. C., Cicin, I., Kim, D. W., Wu, Y. L., Lu, S., Lee, K. H., Pang, Y. K., Zimina, A., Fong, C. H., Poddubskaya, E., Sezer, A., How, S. H., Danchaivijitr, P., Kim, Y., …, & Zaric, B. (2023). Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301. Journal of Clinical Oncology, 41(26), 4208-4217. https://doi.org/10.1200/jco.23.00515
Vancouver
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, et al. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301. Journal of Clinical Oncology. 2023;41(26):4208-4217. doi:10.1200/jco.23.00515
BibTeX
@article{Cho2023,
author = {Cho, Byoung Chul and Ahn, Myung-Ju and Kang, Jin Hyoung and Soo, Ross A and Reungwetwattana, Thanyanan and Yang, James Chih-Hsin and Cicin, Irfan and Kim, Dong-Wan and Wu, Yi-Long and Lu, Shun and Lee, Ki Hyeong and Pang, Yong-Kek and Zimina, Anastasia and Fong, Chin Heng and Poddubskaya, Elena and Sezer, Ahmet and How, Soon Hin and Danchaivijitr, Pongwut and Kim, YuKyung and Lim, Yeji and An, Taewon and Lee, Hana and Byun, Hae Mi and Zaric, Bojan},
title = {Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR -Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {26},
pages = {4208--4217},
doi = {10.1200/jco.23.00515}
}
EUVIMED